

# Resource Summary Report

Generated by [dkNET](#) on Sep 7, 2026

## MDA-MB-415

RRID:CVCL\_0621

Type: Cell Line

### Proper Citation

RRID:CVCL\_0621

### Cell Line Information

**URL:** [https://web.expasy.org/cellosaurus/CVCL\\_0621](https://web.expasy.org/cellosaurus/CVCL_0621)

**Proper Citation:** RRID:CVCL\_0621

**Description:** Cell line MDA-MB-415 is a Cancer cell line with a species of origin Homo sapiens (Human)

**Sex:** Female

**Disease:** Breast adenocarcinoma

**Defining Citation:** [PMID:730202](#), [PMID:6935474](#), [PMID:7272986](#), [PMID:9331070](#), [PMID:10969801](#), [PMID:11343771](#), [PMID:12800145](#), [PMID:16397213](#), [PMID:16541312](#), [PMID:17157791](#), [PMID:18516279](#), [PMID:19593635](#), [PMID:20070913](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:23601657](#), [PMID:24094812](#), [PMID:24162158](#), [PMID:24176112](#), [PMID:25485619](#), [PMID:25877200](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:28196595](#), [PMID:28889351](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

**Comments:** Part of: MD Anderson Cell Lines Project., Part of: JWGray breast cancer cell line panel., Part of: ICBP43 breast cancer cell line panel., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE)., Part of: AKT genetic alteration cell panel (ATCC TCP-1029).

**Category:** Cancer cell line

**Organism:** Homo sapiens (Human)

**Name:** MDA-MB-415

**Synonyms:** MDA-MB415, MDAMB415, MDA-415, MDA415, MD Anderson-Metastatic Breast-415

**Cross References:** BTO:BTO\_0006039, CLO:CLO\_0007637, EFO:EFO\_0001212, CLDB:cl3407, CLDB:cl7127, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2706,

ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, ArrayExpress:E-TABM-157, ArrayExpress:E-TABM-244, ATCC:HTB-128, BioGRID\_ORCS\_Cell\_line:555, BioSample:SAMN03471279, BioSample:SAMN10988336, cancercellines:CVCL\_0621, CCRID:1101HUM-PUMC000350, CCRID:3101HUMTCHu175, Cell\_Model\_Passport:SIDM00630, ChEMBL-Cells:ChEMBL3308760, ChEMBL-Targets:ChEMBL1075498, CLS:305129, Cosmic:871148, Cosmic:894088, Cosmic:897424, Cosmic:904380, Cosmic:924240, Cosmic:949190, Cosmic:1010917, Cosmic:1027054, Cosmic:1044225, Cosmic:1046928, Cosmic:1047697, Cosmic:1090334, Cosmic:1136348, Cosmic:1176650, Cosmic:1287896, Cosmic:1289398, Cosmic:1434954, Cosmic:1502207, Cosmic:1603221, Cosmic:1609460, Cosmic:2165026, Cosmic:2301530, Cosmic:2750527, Cosmic-CLP:924240, DepMap:ACH-000876, EGA:EGAS00001000610, EGA:EGAS00001000978, GDSC:924240, GEO:GSM115101, GEO:GSM149982, GEO:GSM149990, GEO:GSM149998, GEO:GSM186440, GEO:GSM186441, GEO:GSM217588, GEO:GSM344351, GEO:GSM344401, GEO:GSM421876, GEO:GSM783953, GEO:GSM844596, GEO:GSM844597, GEO:GSM844598, GEO:GSM844599, GEO:GSM847415, GEO:GSM847495, GEO:GSM887297, GEO:GSM888372, GEO:GSM1008907, GEO:GSM1053714, GEO:GSM1172981, GEO:GSM1215266, GEO:GSM1238122, GEO:GSM1374656, GEO:GSM1670083, IARC\_TP53:24355, ICLC:HTL02005, LiGeA:CCLE\_116, LINCS\_HMS:50332, LINCS\_LDP:LCL-1469, Lonza:1252, Pharmacodb:MDAMB415\_903\_2019, PRIDE:PXD002486, PRIDE:PXD030304, Progenetix:CVCL\_0621, PubChem\_Cell\_line:CVCL\_0621, SLKBase:3604, Ubigen:YC-D007, Wikidata:Q54904630

**ID:** CVCL\_0621

**Record Creation Time:** 20220427T220755+0000

**Record Last Update:** 20260905T181123+0000

---

## Ratings and Alerts

No rating or validation information has been found for MDA-MB-415.

No alerts have been found for MDA-MB-415.

---

## Data and Source Information

**Source:** [Cellosaurus](#)

---

## Usage and Citation Metrics

We found 11 mentions in open access literature.

**Listed below are recent publications.** The full list is available at [dkNET](#) .

Johnson Thomas AL, et al. (2026) Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer. Molecular oncology.

Zhou W, et al. (2026) Giredestrant immobilizes the estrogen receptor to exert potent antitumor efficacy against ER-active breast cancers. *Cell chemical biology*, 33(6), 785.

Palmer CL, et al. (2025) CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety. *Cancer cell*, 43(3), 464.

Rodina A, et al. (2023) Systems-level analyses of protein-protein interaction network dysfunctions via epichaperomics identify cancer-specific mechanisms of stress adaptation. *Nature communications*, 14(1), 3742.

Spears ME, et al. (2022) De novo sphingolipid biosynthesis necessitates detoxification in cancer cells. *Cell reports*, 40(13), 111415.

Tognetti M, et al. (2021) Deciphering the signaling network of breast cancer improves drug sensitivity prediction. *Cell systems*, 12(5), 401.

Liu Y, et al. (2020) Chemical Biology Toolkit for DCLK1 Reveals Connection to RNA Processing. *Cell chemical biology*, 27(10), 1229.

Yan P, et al. (2020) Molecular Stressors Engender Protein Connectivity Dysfunction through Aberrant N-Glycosylation of a Chaperone. *Cell reports*, 31(13), 107840.

Chopra SS, et al. (2020) Torin2 Exploits Replication and Checkpoint Vulnerabilities to Cause Death of PI3K-Activated Triple-Negative Breast Cancer Cells. *Cell systems*, 10(1), 66.

Johnstone CN, et al. (2020) FGF13 promotes metastasis of triple-negative breast cancer. *International journal of cancer*, 147(1), 230.

Patterson JC, et al. (2019) VISAGE Reveals a Targetable Mitotic Spindle Vulnerability in Cancer Cells. *Cell systems*, 9(1), 74.